GlobeNewswire Inc.··Orion CorporationOrion Lifts 2026 Outlook After Strong Q1 Surge Driven by Nubeqa Royalties
Finnish pharma $ORION reported 17.8% Q1 revenue growth to €417.7M, raised full-year guidance citing Nubeqa royalties and pipeline progress.
OECrevenue growthclinical trial